The C-terminal portion of the nucleocapsid protein demonstrates SARS-CoV antigenicity.
- Author:
Guozhen LIU
1
;
Shaohui HU
;
Yongwu HU
;
Peng CHEN
;
Jianning YIN
;
Jie WEN
;
Jingqiang WANG
;
Liang LIN
;
Jinxiu LIU
;
Bo YOU
;
Ye YIN
;
Shuting LI
;
Hao WANG
;
Yan REN
;
Jia JI
;
Xiaoqian ZHAO
;
Yongqiao SUN
;
Xiaowei ZHANG
;
Jianqiu FANG
;
Jian WANG
;
Siqi LIU
;
Jun YU
;
Heng ZHU
;
Huanming YANG
Author Information
- Publication Type:Journal Article
- MeSH: Antigens, Viral; immunology; Cloning, Molecular; Enzyme-Linked Immunosorbent Assay; Genetic Vectors; Genome, Viral; Humans; Nucleocapsid Proteins; genetics; immunology; Recombinant Fusion Proteins; genetics; isolation & purification; metabolism; SARS Virus; genetics; immunology; Yeasts; genetics
- From: Genomics, Proteomics & Bioinformatics 2003;1(3):193-197
- CountryChina
- Language:English
- Abstract: In order to develop clinical diagnostic tools for rapid detection of the SARS-CoV (severe acute respiratory syndrome-associated coronavirus) and to identify candidate proteins for vaccine development, the C-terminal portion of the nucleocapsid (NC) gene was amplified using RT-PCR from the SARS-CoV genome, cloned into a yeast expression vector (pEGH), and expressed as a glutathione S-transferase (GST) and Hisx6 double-tagged fusion protein under the control of an inducible promoter. Western analysis on the purified protein confirmed the expression and purification of the NC fusion proteins from yeast. To determine its antigenicity, the fusion protein was challenged with serum samples from SARS patients and normal controls. The NC fusion protein demonstrated high antigenicity with high specificity, and therefore, it should have great potential in designing clinical diagnostic tools and provide useful information for vaccine development.
